Equities

Rua Life Sciences PLC

RUA:LSE

Rua Life Sciences PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)11.00
  • Today's Change0.00 / 0.00%
  • Shares traded225.84k
  • 1 Year change-67.65%
  • Beta0.9452
Data delayed at least 20 minutes, as of Jul 05 2024 15:55 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Rua Life Sciences PLC grew revenues 34.09% from 1.63m to 2.18m while net income improved from a loss of 2.07m to a smaller loss of 2.00m.
Gross margin81.97%
Net profit margin-100.05%
Operating margin-135.37%
Return on assets-32.95%
Return on equity-40.56%
Return on investment-36.33%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Rua Life Sciences PLC fell by 1.48m. Cash Flow from Financing totalled 132.00k or 6.06% of revenues. In addition the company used 1.15m for operations while cash used for investing totalled 477.00k.
Cash flow per share-0.0677
Price/Cash flow per share--
Book value per share0.1683
Tangible book value per share0.1347
More ▼

Balance sheet in GBPView more

Rua Life Sciences PLC appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio2.67
Quick ratio2.40
Total debt/total equity0.1192
Total debt/total capital0.1065
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.